MabVax Therapeutics Holdings, Inc.
http://www.mabvax.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MabVax Therapeutics Holdings, Inc.
Publisher’s Spotlight: Citeline Awards Honor R&D Excellence
Pharma Intelligence congratulates the winners of the 2021 Citeline Awards.
Publisher’s Spotlight: Citeline Awards Honor R&D Excellence
Pharma Intelligence congratulates the winners of the 2021 Citeline Awards.
Scrip Asks…What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances
Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.
UCB Advances Two-Drug Strategy For Myasthenia Gravis
Successful Phase III data for UCB’s C5 inhibitor zilucoplan adds to a similarly positive Phase III readout for its rozanolixizumab in December, but details are lacking. UCB is the only company with two mechanisms for MG.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- MabVax Therapeutics, Inc.
- Telik, Inc.